Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Caresse Haaser, Rebecca Zisser / Axios

After months of circular finger-pointing over high drug prices, lawmakers, administration officials and parts of the health care industry seem to have settled on an initial target: pharmacy benefit managers, the middlemen that health insurers and employers hire to negotiate with drug companies.

Yes, but: There are savings to be wrung out of the highly concentrated PBM industry. That's why insurers are so eager to operate their own PBMs. But analysts say squeezing PBMs won't solve some of the fundamental problems that drive high drug spending.

What Washington is doing: Health and Human Services Secretary Alex Azar and FDA Commissioner Scott Gottlieb both had strong words for PBMs and insurers last week. Gottlieb said they misuse the rebates PBMs negotiate on drugs, and rely on a "short-term profit goose" rather than bringing down consumers' drug costs.

  • Azar and Gottlieb want PBMs and health plans to pass on more of those savings to consumers when they pick up their prescriptions at the pharmacy.
  • UnitedHealthcare said last week it would start doing so, in a limited fashion.

Several members of Congress also have called out PBMs over the past year.

What pharma is doing: The pharmaceutical industry, meanwhile, has consistently cast PBMs as the villains in its year-long lobbying campaign to prevent the government from cracking down on prices.

  • "It's clear the knives are out for (PBMs) politically as a way for pharma to save their own pricing practices," said Andrea Harris, a health care analyst at Height Capital Markets.

What insurers are doing: Merging with PBMs.

  • Cigna's pending $52 billion acquisition of Express Scripts followed the proposed merger of CVS Health and Aetna. And these deals come roughly three years after UnitedHealth Group's OptumRx bought Catamaran.
  • If those deals clear antitrust review, the three largest PBMs in the country — Express Scripts, CVS and OptumRx — would all be tied to the hip of health insurance conglomerates.

Combining insurers and PBMs under one roof was the status quo a decade ago, and it makes some sense. It leaves one fewer mouth that needs to be fed profit, and offering medical and prescription drug benefits together is less disjointed.

But these deals are about gaining an upper hand in negotiations with drug companies and could spur pharmaceutical makers to pursue their own round of mega-mergers. No company enjoys losing negotiating leverage.

The intrigue: PBMs have helped bring down net spending on some drugs, according to data from industry reports. But they also have profited from secretive rebates and raised concerns about whether they have exploited their market power. Changing PBM structures could help people who are struggling to pay for their medicine.

The catch: Squeezing the middleman can only go so far.

  • PBMs negotiate rebates off a drug's list price. That process begins with high list prices, and drug companies are still free to jack up those numbers at will.
  • There's no guarantee higher rebate amounts will actually go back to patients, and insurers can easily raise their premiums to offset any rebates they have to dish out at the pharmacy.

"If there is increased clout, leading to lower drug prices from pharmaceutical companies, will they pass those savings on to consumers? We don’t know that," said Ben Gomes-Casseres, a professor at the Brandeis International Business School who studies mergers.

Go deeper

17 mins ago - Health

Biden gets COVID-19 booster shot on live television

President Biden received a Pfizer-BioNTech coronavirus vaccine booster shot on live television on Monday, while also urging Americans to get vaccinated.

Driving the news: The Centers for Disease Control and Prevention last week recommended Pfizer booster shots for millions of people, including those 65 years and older and individuals at high-risk of severe COVID-19.

John Hinckley, who shot Reagan, wins unconditional release

John Hinckley Jr. sitting on the back seat of a car in 1981. Photo: Bettmann/Getty Images

A federal judge on Monday approved the unconditional release of John Hinckley Jr., who tried to assassinate former President Reagan in 1981.

State of play: U.S. District Court Judge Paul L. Friedman in Washington ruled that Hinckley can be freed from all court supervision in 2022 if he remains mentally stable and continues to follow rules that were imposed on him after he was released from a Washington mental health facility in 2016 to live in Virginia, AP reports.

Rep. Karen Bass launches run for Los Angeles mayor

Photo: Tom Williams/CQ-Roll Call, Inc via Getty Images

Rep. Karen Bass (D-Calif.) on Monday launched her bid for mayor of Los Angeles.

Why it matters: Bass is a high-profile member of Congress. The former chair of the Congressional Black Caucus, she was considered as a potential running mate to President Joe Biden and was a lead negotiator in the recently-ended talks on police reform. Should Bass win the mayoral election, she would become the first female mayor in L.A. history.